By Clare Leek on January 27, 2025
The advanced, user-friendly system is set to revolutionise diabetes management with its affordability, simplicity and cutting-edge features – offering more choice for people with diabetes.
CareSens Air is a 15-day wear device that delivers glucose readings directly to a user’s smartphone, enabling real-time monitoring and empowering users to take control of their -health. With a slim, lightweight design and all-in-one applicator, the system ensures a seamless experience for individuals living with diabetes.
Chris Barker, Chief Executive of Spirit Health, said: “We’re thrilled to bring CareSens Air to the Drug Tariff this February. This innovative device bridges critical gaps in diabetes care by offering a reliable, user-friendly tool that enhances patient outcomes while being mindful of healthcare budgets helping us make healthcare simple and more accessible for all.”
According to prescription data, the UK CGM market is currently dominated by Abbott, which accounts for 95 per cent of sales, with Dexcom holding a four per cent share. CareSens Air enables an additional choice for these patients in the future.
Dedicated to making healthcare simple, accessible, and affordable, the launch of CareSens Air aligns with Spirit Health’s determination to support patients and healthcare providers with impactful, cost-effective solutions.
The CareSens Air app elevates diabetes management with features including real-time trend tracking, personalised alerts for glucose levels, and lifelong integration to help users understand how daily activities influence their health. The app’s remote monitoring capability also allows healthcare professionals and carers to access live glucose data, detailed reports, and actionable insights, supporting proactive patient care.
